Pharmaceutical company Krka has announced its arrival in the UK animal health market by launching the country’s first generic fipronil/S-methoprene treatment.
Amflee Combo is, says the Slovenian-based firm, “a direct alternative to Merial’s very successful Frontline Combo” and will allow vets to have a wider range of POM-V products when discussing flea and tick control options with clients.
Krka is among the top five generic pharmaceutical companies in the world and its products are sold in 70 countries. It says Amflee Combo will be the first of a range of small and production animal products to reach the UK market in the coming years.
Killian Gaffney, head of sales and marketing at Krka, stressed the company would be supporting UK vets by offering high-quality products, building business relationships that helped protect veterinary incomes and offering good value to customers.
He said: “Amflee Combo has some unique features that we believe will set it apart from the competition. We know the combination of the two active ingredients in Amflee Combo is very effective for the treatment of fleas, ticks and biting lice and part of a treatment strategy for flea allergy dermatitis in dogs and cats. S-methoprene is also effective against flea eggs and larvae in the environment.
“However, these ingredients can be susceptible to degradation when subjected to light and moisture, which is why each Amflee Combo pipette comes in its own special foil wrapper. The pipettes have also been designed for convenience of use, since we know only 22% of owners apply spot-ons correctly1.”
Variety of pack sizes
Krka has launched Amflee Combo in a variety of packs for cats and different-sized dogs, with three or six easy-to-use ergonomic pipettes. One pipette is recommended every four weeks.
The firm says a range of product and client literature is available to veterinary practices by calling 01753 722150. Further information on the product and Krka is available at www.krka.co.uk